Trop-2靶向ADC再获突破性疗法认定，治疗难治性肺癌_腾讯新闻
1 天前 · 01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌(ES-SCLC)成人患者。. 02 Trodelvy是 ...
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy ...
3 天之前 · For people with ES-SCLC whose disease does not respond to current first-line standard of care (platinum-based chemotherapy or immunotherapy), the prognosis is often poor, and treatment options are limited. There is an urgent need for new and more effective approaches to care that can improve survival and slow the progression of the disease.
FDA Grants Breakthrough Therapy Designation to Sacituzumab …
2 天之前 · Safety Data With Sacituzumab Govitecan in ES-SCLC. ... for second-line treatment of extensive-stage small cell lung cancer. News Release. Gilead. December 17, 2024. Accessed December 17, 2024. ...
储天晴教授盘点 2023 年度小细胞肺癌进展：免疫治疗精益求精， …
2024年2月3日 · 随着免疫治疗在 ES-SCLC 治疗领域的突破，其治疗发生了较大改变，在此次 2023 年肺癌领域的热词揭晓中，ES-SCLC 的免疫治疗也一跃上榜成为第五位。 因此， 上海交通大学附属胸科医院储天晴教授 分享了 2023 SCLC 的年度进展，并就 SCLC 的治疗新格局进行点评。 此外， 南京医科大学第一附属医院郭人花教授、南京大学医学院附属金陵医院吕镗烽教授、上海市肺科医院李玮教授、上海市肺科医院李嘉瑜博士 就 ES-SCLC 的热点问题进行了圆桌讨 …
Recent advances and future strategies in first-line treatment of ES-SCLC
2023年12月5日 · Recent advancements in treating extensive-stage small-cell lung cancer (ES-SCLC) have been significantly marked by incorporating immune checkpoint inhibitors (ICIs) into platinum-based chemotherapy, leading to modest yet notable improvements in patient outcomes, which become more evident with longer follow-up.
Navigating treatment combinations in small-cell lung cancer
2024年9月18日 · In recent years, although a combination of immune checkpoint inhibitors (ICIs) and chemotherapy has been established for ES-SCLC, the improvement in survival outcomes has been modest — with...
Extensive-stage small-cell lung cancer: Current management and …
2023年6月1日 · Extensive-stage small-cell lung cancer (ES-SCLC) is regarded as a refractory carcinoma associated with extremely rapid disease progression. After more than three decades without clinical advances, research on immune checkpoint inhibitors (ICIs) combined with platinum-based chemotherapy has led to th …
Sacituzumab Govitecan Earns Breakthrough Therapy Designation in ES-SCLC
2 天之前 · Sacituzumab govitecan-hziy (Trodelvy) has been granted the breakthrough therapy designation by the FDA for the treatment of adult patients who have extensive-stage small cell lung cancer (ES-SCLC) and have experienced disease progression on or following platinum-based chemotherapy, according to a press release from the developer, Gilead. 1 The trial agent is the first, and only, currently ...
FDA grants accelerated approval to tarlatamab-dlle for lung cancer
On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease ...
Small-cell lung cancer - Latest research and news | Nature
2024年11月19日 · Small-cell lung cancer is a highly malignant form of lung cancer, also known as oat-cell carcinoma, that accounts for approximately 15% of lung cancer cases. Composed...
- 某些结果已被删除